Cardiovascular risk estimation with 5 different algorithms before and after 5 years of bDMARD treatment in rheumatoid arthritis

2020 ◽  
Vol 50 (12) ◽  
Author(s):  
Fabio Cacciapaglia ◽  
Marco Fornaro ◽  
Vincenzo Venerito ◽  
Simone Perniola ◽  
Livio Urso ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Cardiovascular Risk ◽  
Risk Estimation ◽  
Before And After ◽  
Cardiovascular Risk Estimation

scholarly journals AB0323 CARDIOVASCULAR RISK ESTIMATION IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH BIOLOGICS OR C-DMARDS

2019 ◽  
Author(s):  
Evangelia Mole ◽  
Sousana Gazi ◽  
Dimitra Moschou ◽  
Georgia Mpaili ◽  
Stavros Theodorakopoulos ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Cardiovascular Risk ◽  
Risk Estimation ◽  
Cardiovascular Risk Estimation

SAT0148 Cardiovascular Risk Estimation in Rheumatoid Arthritis: What is Missing in Traditional Risk Estimators?: Table 1.

2014 ◽  
Vol 73 (Suppl 2) ◽  
pp. 644.1-644
Author(s):  
G. Ozen ◽  
M. Sunbul ◽  
P. Atagunduz ◽  
H. Direskeneli ◽  
K. Tigen ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Cardiovascular Risk ◽  
Risk Estimation ◽  
Cardiovascular Risk Estimation

Skin autofluorescence as a tool for cardiovascular risk estimation in patients with rheumatoid arthritis

2019 ◽  
Vol 66 ◽  
pp. e7-e8
Author(s):  
S.H. Bakker-Aling ◽  
J.M. van Woerkom ◽  
T.P. Zomer ◽  
H.C.J.L. Buscher ◽  
T. van Bemmel
Keyword(s):  
Rheumatoid Arthritis ◽  
Cardiovascular Risk ◽  
Risk Estimation ◽  
Skin Autofluorescence ◽  
Cardiovascular Risk Estimation

Peculiarities of cardiovascular risk estimation in rheumatoid arthritis patients

Therapy ◽  
2018 ◽  
Vol 5_2018 ◽  
pp. 104-108
Author(s):  
T.A. Romanova Romanova ◽  
N.M. Nikitina Nikitina ◽  
A.P. Rebrov Rebrov ◽  
Keyword(s):  
Rheumatoid Arthritis ◽  
Cardiovascular Risk ◽  
Risk Estimation ◽  
Cardiovascular Risk Estimation

Cardiovascular risk estimation at the individual level

ESC CardioMed ◽  
2018 ◽  
pp. 846-863
Author(s):  
Yvo M. Smulders ◽  
Marie-Therese Cooney ◽  
Ian Graham
Keyword(s):  
Cardiovascular Disease ◽  
Cardiovascular Risk ◽  
High Risk ◽  
Risk Estimation ◽  
Pharmacological Therapy ◽  
Cardiovascular Risks ◽  
Individual Level ◽  
The Individual ◽  
Very High ◽  
Cardiovascular Risk Estimation

The absolute benefit of any measure to prevent cardiovascular disease, be it lifestyle improvement or pharmacological therapy, depends on the baseline cardiovascular risk. This risk cannot be assessed exactly, but only be estimated because many known risk determinants cannot be accounted for in existing risk scoring systems, and because the application to an individual of risk estimates derived from populations is imprecise. Several cardiovascular risk estimation methods are available, and the European Society of Cardiology has favoured the European-based Systematic COronary Risk Evaluation (SCORE) system as a basis for their cardiovascular disease prevention guidelines. SCORE estimates absolute 10-year cardiovascular mortality risk. In specific circumstances, estimation of relative risk, risk age, or lifetime risk may be considered. High- and very-high-risk population are defined by SCORE risks greater than 5% and greater than 10%, respectively, or by clinical conditions conferring (very) high risk, such as existing cardiovascular disease or chronic kidney disease. The role of additional risk information on top of the information entered in SCORE is generally limited. In particular, markers of early cardiovascular damage should be collected and interpreted with caution. Absolute cardiovascular risks in young and elderly individuals are almost always low or very high, respectively, and the options for appropriate interpretation and management of these risks are discussed.

Sign in / Sign up

Export Citation Format

Share Document